The Covid-19 pandemic provides new opportunities for the company to provide medical solutions and introduce Covid-19 test such as antibody Rapid Test Kit (“RTK”) and Polymerase Chain Reaction (“PCR”) molecular diagnosis screening. The official distribution rights for Healgen and Liangrun antibody RTK have gained traction from government and private sector. The Polymerase Chain Reaction PCR reagents are recognised by WHO and FDA which the Company has submitted to Medical Device Authority for approval. This is evidence from continuous repeat orders for the company services during pandemic. Despite the challenges, the Company is cautiously optimistic that the long-term outlook for the company continues to remain positive as we continuously introduce innovative services in the country and as well as within our regional presence.
Valuation Nexgram Holdings Berhad undervalued compared to its fair value and its price relative to the market? Analysis Checks 1/6 0.42x Price to Book (PB) ratio
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
OKU_2020
4,786 posts
Posted by OKU_2020 > 2020-06-30 10:28 | Report Abuse
# 8dragon.....what do u expect from this non stop bleeding cap ayam - holland nexgram